Acquiring Company
Hikma Pharmaceuticals
Acquired Company
Novugen
Ohio
United Arab EmiratesManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareDescription
Hikma Pharmaceuticals has acquired the FDA-approved ANDA for trametinib from Novugen. This acquisition allows Hikma to enhance its US product pipeline and market presence in oncology treatments. Hikma will be responsible for US sales and marketing, while Novugen will manufacture the product. The move is part of Hikma's strategy to expand access to essential medicines.
Who to call at Hikma Pharmaceuticals, and when
When Hikma Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Hikma Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hikma Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hikma Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hikma Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Novugen?
Novugen was acquired by Hikma Pharmaceuticals, based in Ohio. The deal was reported on April 17, 2025. Hikma Pharmaceuticals is a leading player in the U.S. generic drug market. Hikma Pharmaceuticals is privately held and operates in Manufacturing.
When did Hikma Pharmaceuticals acquire Novugen?
Hikma Pharmaceuticals's acquisition of Novugen was reported on April 17, 2025. Hikma Pharmaceuticals has acquired the FDA-approved ANDA for trametinib from Novugen. This acquisition allows Hikma to enhance its US product pipeline and market presence in oncology treatments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Novugen do?
Novugen is a wholly owned subsidiary of SciTech International, with over 30 years of expertise in the healthcare industry. The company focuses on innovative healthcare solutions and aims to ensure the availability of effective oncology treatments. It is privately held, operating in Biotechnology, and is based in United Arab Emirates.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.